Background. Incidental 18F-FDG uptake in the thyroid on PET-CT examinations represents a diagnostic challenge. The maximal standardized uptake value (SUV_{max}) is one possible parameter that can help in distinguishing between benign and malignant thyroid PET lesions.

Patients and methods. We retrospectively evaluated 18F-FDG PET-CT examinations of 5,911 patients performed at two different medical centres from 2010 to 2011. If pathologically increased activity was accidentally detected in the thyroid, the SUV_{max} of the thyroid lesion was calculated. Patients with incidental 18F-FDG uptake in the thyroid were instructed to visit a thyroidologist, who performed further investigation including fine needle aspiration cytology (FNAC) if needed. Lesions deemed suspicious after FNAC were referred for surgery.

Results. Incidental 18F-FDG uptake in the thyroid was found in 3.89% — in 230 out of 5,911 patients investigated on PET-CT. Malignant thyroid lesions (represented with focal thyroid uptake) were detected in 10 of 66 patients (in 15.2%). In the first medical centre the SUV_{max} of 36 benign lesions was 5.6 ± 2.8 compared to 15.8 ± 9.2 of 5 malignant lesions (p < 0.001). In the second centre the SUV_{max} of 20 benign lesions was 3.7 ± 2.2 compared to 5.1 ± 2.3 of 5 malignant lesions (p = 0.217). All 29 further investigated diffuse thyroid lesions were benign.

Conclusions. Incidental 18F-FDG uptake in the thyroid was found in 3.89% of patients who had a PET-CT examination. Only focal thyroid uptake represented a malignant lesion in our study — in 15.2% of all focal thyroid lesions. SUV_{max} should only serve as one of several parameters that alert the clinician on the possibility of thyroid malignancy.

Key words: thyroid; 18F-FDG; PET-CT; PET incidentaloma; thyroid cancer

Introduction

Incidental uptake of 18F-fluorodeoxyglucose (18F-FDG) in the thyroid is sometimes found during positron emission tomography - computed tomography (PET-CT), which is mostly used in cancer staging and diagnostics. Throughout the literature the reported incidence of incidental thyroid uptake of 18F-FDG on PET-CT varies between 0.2% and 8.9%. Thyroid lesions on PET-CT can be either diffuse or focal (Figure 1). Diffuse 18F-FDG uptake is usually associated with autoimmune thyroiditis or Graves' disease, whereas focal 18F-FDG uptake can be either due to a benign or malignant process in the thyroid.

A semi-quantitative parameter that could help in differentiating thyroid lesions on PET-CT is the standardized uptake value (SUV), often expressed as the maximal SUV (SUV_{max}) or mean SUV (SUV_{mean}). However, the discriminating power of this parameter is still unclear, as some studies have reported a statistically significant difference between SUV values of benign and malignant thyroid lesions, whilst others have shown no statistically significant difference. Moreover, the SUV of benign and malignant thyroid lesions varied greatly between these studies. We also know that the calculated SUV is highly dependent on the scanner type, reconstruction algorithms and...
software packages used, which prevents the comparisons of studies conducted at different centres using different equipment. This represented a challenge for our study.

The aims of this study were to (i) determine the incidence of thyroid lesions incidentally found on $^{18}$F-FDG PET-CT, (ii) identify what diffuse and focal thyroid lesions represent, and (iii) what is the optimal $SUV_{max}$ that can discriminate between benign and malignant focal thyroid lesions incidentally found on PET-CT. This study was conducted at two PET-CT centres (having different PET-CT scanners) in Slovenia: the Department of nuclear medicine at the University Medical Centre Ljubljana (UMC) and the Institute of Oncology Ljubljana (IO).

**Patients and methods**

**Subjects and study design**

We retrospectively evaluated the medical records of 5,911 patients (2,840 patients from UMC and 3,071 patients from IO) who underwent an $^{18}$F-FDG PET-CT investigation between January 2010 and December 2011. Only patients (males and non-pregnant females) aged 18 years or more were included in this study. The $^{18}$F-FDG PET-CT investigation of patients included in the study was performed for different purposes, mainly because of oncologic indications. The study was approved by the Ethics Committee at the Ministry of Health, Republic of Slovenia (No.: 53/04/12).

**Methods employed**

Patients from both centres fasted for at least 6 hours, ideally having a blood glucose level less than 7 mmol/l, before receiving 370 MBq of $^{18}$F-FDG. The acquisition on the PET-CT scanner started 60 minutes after the radiotracer administration. The PET-CT scanners used were different: at UMC a Siemens Biograph mCT and at IO a Philips Gemini 16 GXL. In all patients, the localisation and attenuation correction CT was first done, followed by the PET scan itself. The CT acquisition parameters in both centres were fairly similar. Also, the PET acquisition parameters did not differ a lot; at UMC a bed position of 2 min with 45% overlap and at IO a bed position of 2 min with 50% overlap was used. The acquired PET-CT data was processed using similar iterative reconstruction algorithms.

Nuclear medicine doctors at both centres used visual and semi-quantitative data analysis ($SUV_{max}$) for creating a final report. They had access to relevant patient history and previous examination reports. Patients with thyroid lesion incidentally found on $^{18}$F-FDG PET-CT were referred to a thyroidologist.

Thyroid investigation normally included the patient’s history, clinical examination, relevant laboratory workup, ultrasound examination and $^{99m}$Tc scintigraphy of the thyroid. For a final diagnosis of suspicious thyroid lesions, patients were further investigated using fine needle aspiration cytology (FNAC). A histological report was obtained for lesions that were surgically removed. All data (PET-CT reports, reports of thyroid examinations, cytological and histological reports) were obtained only from patients treated and followed-up at UMC and IO.

**Statistical analyses**

Statistical analysis was performed using IBM SPSS Statistics 22.0 and Microsoft Excel for Mac 14.1. The $SUV_{max}$ of benign and malignant thyroid lesions were compared using Student’s $t$-test. Results were deemed statistically significant for $p < 0.05$. A receiver operating characteristic (ROC) analysis was performed to determine a $SUV_{max}$ cut-off point that differentiates between suspicious and unsuspicious focal thyroid lesions.

**Results**

**Characteristics of patients**

The mean age of 2,840 patients who had a PET-CT investigation at UMC was 61.2 ± 12.9 years; the mean age of 3,071 patients at IO was 64.4 ± 12.1...
Incidentally detected thyroid lesions

Incidental ¹⁸F-FDG uptake in the thyroid was found in 230 out of 5,911 investigated patients (in 3.89%). Focal thyroid uptake represented 64.3% and diffuse thyroid uptake 35.7% of detected thyroid lesions. 56.1% of all focal lesions and 81.7% of all diffuse lesions were detected in female patients. More detailed information about patients with incidentally found thyroid lesions on ¹⁸F-FDG PET-CT is presented in Table 1.

Data of further treatment were found for 58 out of 82 patients (in 70.7%) with increased ¹⁸F-FDG uptake in the thyroid investigated at UMC and for 46 out of 148 patients (in 31.1%) investigated at IO. Diffuse thyroid lesions in 14/58 patients (24.1%) from UMC (SUV_{max} range from 3.5 to 10.3) and in 15/46 (32.6%) patients from IO (SUV_{max} range from 1.9 to 9.2) were all benign. Hashimoto’s thyroiditis was diagnosed in 92.9% and 73.3% respectively.

At UMC, 44 patients with focal ¹⁸F-FDG uptake in the thyroid (SUV_{max} range from 2.3 to 31.9) were further investigated. Thyroid nodules were found in 30 patients (in 68.2%). Autoimmune thyroid disease was diagnosed in 29.5% – in 12 patients with Hashimoto’s thyroiditis and in one patient with Graves’ disease. One patient was diagnosed to have benign diffuse goitre. FNAC was performed in 28 of 44 patients (63.6%). Results of FNAC are presented in Table 2.

Out of 31 focal thyroid lesions diagnosed on PET-CT in patients from IO (SUV_{max} range from 1.5 to 8.7) thyroid nodules were found in 28 cases (in 90.3%). In two patients the focal lesion was caused by Hashimoto’s thyroiditis and in one by Graves’ disease. FNAC diagnostics were performed in 24 of 31 patients (77.4%) (Table 2).

The optimal SUV_{max} cut-off point for differentiating between suspicious and unsuspicious focal thyroid lesions incidentally detected on PET-CT, calculated using ROC analysis, was 5.4 for patients investigated at UMC (sensitivity 76.9%, specificity 61.3%, AUC = 0.785); the optimal differentiating SUV_{max} for patients investigated at IO was 4.0 (sensitivity 66.7%, specificity 73.7%, AUC = 0.754).

TABLE 1. Patients and characteristics of incidental ¹⁸F-FDG uptake in the thyroid detected by PET-CT

<table>
<thead>
<tr>
<th>Centre</th>
<th>Number (m/f)</th>
<th>Incidence (%)</th>
<th>Age (year) (average ± SD)</th>
<th>Type</th>
<th>SUV_{max} (average ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UMC</td>
<td>61 (24/37)</td>
<td>2.15</td>
<td>63.6 ± 12.1</td>
<td>Focal</td>
<td>6.6 ± 4.4</td>
</tr>
<tr>
<td>(all)</td>
<td>82 (28/54)</td>
<td>2.89</td>
<td>62 ± 12.9</td>
<td>Diffuse</td>
<td>7.9 ± 4.0</td>
</tr>
<tr>
<td>IO</td>
<td>87 (41/46)</td>
<td>2.83</td>
<td>64.2 ± 12.3</td>
<td>Focal</td>
<td>6.9 ± 4.3</td>
</tr>
<tr>
<td>(all)</td>
<td>148 (52/96)</td>
<td>4.82</td>
<td>64.5 ± 11.8</td>
<td>Diffuse</td>
<td>4.2 ± 2.3</td>
</tr>
</tbody>
</table>

UMC = University Medical Centre Ljubljana; IO = Institute of Oncology Ljubljana; SUV_{max} = maximal standardised uptake value

TABLE 2. Results of fine needle aspiration cytology for focal thyroid lesions, classified according to the Bethesda classification

<table>
<thead>
<tr>
<th>Centre</th>
<th>FNAC (No.)</th>
<th>ND or UnS (No. (%))</th>
<th>BEN (No. (%))</th>
<th>AUS or FLUS (No. (%))</th>
<th>FN (No. (%))</th>
<th>SM (No. (%))</th>
<th>M (No. (%))</th>
</tr>
</thead>
<tbody>
<tr>
<td>UMC</td>
<td>28</td>
<td>2 (7.1)</td>
<td>17 (60.8)</td>
<td>2 (7.1)</td>
<td>5 (17.9)</td>
<td>0</td>
<td>2 (7.1)</td>
</tr>
<tr>
<td>IO</td>
<td>24</td>
<td>5 (20.8)</td>
<td>7 (29.2)</td>
<td>1 (4.2)</td>
<td>3 (12.5)</td>
<td>3 (12.5)</td>
<td>5 (20.8)</td>
</tr>
<tr>
<td>All</td>
<td>52</td>
<td>7 (13.4)</td>
<td>24 (46.2)</td>
<td>3 (5.8)</td>
<td>8 (15.4)</td>
<td>3 (5.8)</td>
<td>7 (13.4)</td>
</tr>
</tbody>
</table>

FNAC = fine needle aspiration cytology; ND or UnS = non-diagnostic or unsatisfactory; BEN = benign; AUS or FLUS = atypia of undetermined significance or follicular lesion of undetermined significance; FN = follicular neoplasms and oncocytic tumours; SM = suspicious for malignancy; M = malignant
Surgically removed focal thyroid lesions

Malignant thyroid disease was found in 10 out of 18 patients (55.6%) who underwent surgery. Malignant thyroid disease was more common in males (8 cases) than in females (2 cases). Nine patients with focal thyroid lesions who were referred for surgery were lost to follow-up. Therefore in 10 out of 66 patients (15.2%) with focal thyroid lesion incidentally detected on $^{18}$F-FDG PET-CT malignant thyroid disease was confirmed. Detailed characteristics of all surgically removed thyroid lesions are presented in Table 3.

$SUV_{\text{max}}$ of malignant and benign focal thyroid lesions

$SUV_{\text{max}}$ of malignant focal lesions (histologically confirmed) was compared to $SUV_{\text{max}}$ of benign focal lesions (the benign nature of a lesion was established either after a thorough thyroid examination with ultrasound, FNAC or surgical treatment) (Figure 2). A statistically significant ($p < 0.001$) difference was observed between 36 benign ($SUV_{\text{max}}$ from 2.3 to 13.2) and 5 malignant ($SUV_{\text{max}}$ from 10 to 31.9) focal thyroid lesions incidentally detected on PET-CT in patients from UMC. No statistically significant difference ($p = 0.217$) was observed between 20 benign ($SUV_{\text{max}}$ from 1.5 to 8.8) and 5 malignant ($SUV_{\text{max}}$ from 2.7 to 7.8) focal thyroid lesions in patients from IO.

Discussion

Incidental $^{18}$F-FDG uptake in the thyroid was observed in 3.89% of 5,911 patients investigated; in 2.89% of patients investigated at UMC and in 4.82% of patients investigated at IO. This is in accordance with the present literature, where the incidence of such lesions varied from 0.2 to 8.9%, with most studies reporting a incidence between 2 and 3%. According to a review article by Bertagna et al., the authors postulated that this variability in incidence could be attributed to population characteristics and background risk of thyroid disease related to specific geographic areas.

Slovenia, although not an endemic goitre region, still has a significant incidence of thyroid nodules in the general population. This could in part explain the slightly higher incidence of thyroid lesions incidentally found on PET-CT compared to some studies, where authors found a smaller incidence of thyroid lesions.

According to the American Thyroid Association Guidelines Taskforce further investigation of incidentally found thyroid nodules is recommended. Adhering to these guidelines, all patients from our practices with an incidentally detected thyroid lesion on PET-CT were referred to a thyroidologist. Due to different reasons, not all patients had a consultation, mainly because of the management of their primary illness. In our study, 71% of patients from UMC and only 31% of patients from IO received additional thyroid diagnostics. Our explanation for this difference is that PET-CT examinations in patients at IO were done almost exclusively for staging of known primary malignant diseases – many of these patients had more severe primary malignancies that required more prompt treatment than potential thyroid neoplasms. In comparison at UMC, approximately one third of PET-CT examinations were done for non-oncologic indications in which cases additional thyroid diagnostics were more likely than in oncologic patients with more severe primary disease. Other studies also reported a similar percentage of patients with incidentally discovered thyroid PET lesions who were further investigated, with follow-up rates in the ranks of 50%. Our explanation for this difference is that PET-CT examinations in patients at IO were done almost exclusively for staging of known primary malignant diseases – many of these patients had more severe primary malignancies that required more prompt treatment than potential thyroid neoplasms. In comparison at UMC, approximately one third of PET-CT examinations were done for non-oncologic indications in which cases additional thyroid diagnostics were more likely than in oncologic patients with more severe primary disease. Other studies also reported a similar percentage of patients with incidentally discovered thyroid PET lesions who were further investigated, with follow-up rates in the ranks of 50%. Our explanation for this difference is that PET-CT examinations in patients at IO were done almost exclusively for staging of known primary malignant diseases – many of these patients had more severe primary malignancies that required more prompt treatment than potential thyroid neoplasms. In comparison at UMC, approximately one third of PET-CT examinations were done for non-oncologic indications in which cases additional thyroid diagnostics were more likely than in oncologic patients with more severe primary disease. Other studies also reported a similar percentage of patients with incidentally discovered thyroid PET lesions who were further investigated, with follow-up rates in the ranks of 50%

Experts agree that diffuse thyroid uptake of $^{18}$F-FDG on PET-CT is associated with Hashimoto’s thyroiditis. This was also confirmed by our results, where most diffuse lesions were caused by Hashimoto’s thyroiditis and no malignancy was found in patients with diffuse thyroid PET lesions. According to the literature, the rate of focal lesions ranges from 14% to 73% of all thyroid PET lesions with a risk of malignancy in further investigated lesions of about 33%. In our study, focal thyroid lesions were present in 64.3% of all cases with incidental thyroid uptake. These lesions represented a thyroid nodule in 68.2% (UMC patients) and in 90.3% (IO patients). We histologically confirmed thyroid malignancy in 5 of 10 surgically treated patients from UMC and in 5 of 8 patients from IO. Altogether, malignant disease was observed in 10 of 66 patients (15.2%) with a focal $^{18}$F-FDG uptake in the thyroid. In comparison to other reports, the incidence of thyroid malignancy in our study was somewhat lower. This is, in our opinion, mainly due to higher goitre prevalence in our population. Autoimmune thyroid disease was present in 29.5% of focal thyroid lesions from UMC patients. This finding is quite different from data published in the literature. Our explanation for this discrepancy is in the different diagnostic process.
that was used in different institutions. At UMC, a thorough thyroid examination with relevant laboratory workup and an ultrasound examination of the thyroid, irrespective of the use of FNAC, was in most patients enough to make a final diagnosis of thyroid disease. The decision regarding FNAC examination was undertaken by the consulting thyroidologist on a patient by patient basis. Most studies, like the one conducted by Chu et al., were more in line with the IO group, where only 3 of 31 focal PET lesions proved to be of autoimmune origin.

According to the literature, Graves’ disease is demonstrated most commonly by diffuse-ly increased 18F-FDG uptake in the thyroid. However, in our study, we found two cases of Graves’ disease with focal 18F-FDG uptake.

One of the main goals of our study was to determine whether it would be possible to differentiate between benign and malignant thyroid le-

<table>
<thead>
<tr>
<th>Centre</th>
<th>Referral diagnosis</th>
<th>Sex (m/f)</th>
<th>Age (year)</th>
<th>SUV&lt;sub&gt;max&lt;/sub&gt;</th>
<th>Size (mm)</th>
<th>Cytology</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>UMC</td>
<td>Gastric carcinoma</td>
<td>f</td>
<td>71</td>
<td>5.5</td>
<td>10</td>
<td>Oncocytic cells</td>
<td>Hürthle adenoma</td>
</tr>
<tr>
<td></td>
<td>Suspicious lesion in the right lungs</td>
<td>m</td>
<td>68</td>
<td>4.8</td>
<td>12</td>
<td>Unsatisfactory</td>
<td>Nodular goitre</td>
</tr>
<tr>
<td></td>
<td>Tumour of the cardia</td>
<td>f</td>
<td>48</td>
<td>8.9</td>
<td>9</td>
<td>Oncocytic cells</td>
<td>Hürthle adenoma</td>
</tr>
<tr>
<td></td>
<td>Erythema nodosum and pharyngitis</td>
<td>f</td>
<td>40</td>
<td>7.5</td>
<td>22</td>
<td>Unsatisfactory</td>
<td>Hürthle adenoma</td>
</tr>
<tr>
<td></td>
<td>Pelvic inflammatory disease</td>
<td>f</td>
<td>61</td>
<td>6.4</td>
<td>10</td>
<td>Oncocytic cells</td>
<td>Nodular goitre</td>
</tr>
<tr>
<td></td>
<td>Lung carcinoma</td>
<td>m</td>
<td>70</td>
<td>15.2</td>
<td>30</td>
<td>Oncocytic cells</td>
<td>Follicular carcinoma</td>
</tr>
<tr>
<td></td>
<td>Origo ignota malignant disease</td>
<td>m</td>
<td>48</td>
<td>11</td>
<td>21</td>
<td>Atypia of undetermined significance</td>
<td>Medullary carcinoma</td>
</tr>
<tr>
<td></td>
<td>Histiocytosis</td>
<td>m</td>
<td>41</td>
<td>11</td>
<td>10</td>
<td>Papillary carcinoma</td>
<td>Papillary carcinoma</td>
</tr>
<tr>
<td></td>
<td>GIT malignancy</td>
<td>f</td>
<td>64</td>
<td>31.9</td>
<td>52</td>
<td>Atypia of undetermined significance</td>
<td>Papillary carcinoma</td>
</tr>
<tr>
<td></td>
<td>Metastatic lesion on the left side of the neck</td>
<td>m</td>
<td>74</td>
<td>10</td>
<td>30</td>
<td>Plano cellular metastasis</td>
<td>Plano cellular subglottic carcinoma – metastasis</td>
</tr>
<tr>
<td></td>
<td>Hodgkin’s lymphoma</td>
<td>f</td>
<td>64</td>
<td>3.2</td>
<td>15</td>
<td>Suspicious for malignancy (follicular or Hürthle)</td>
<td>Hyperplastic follicular benign nodule</td>
</tr>
<tr>
<td></td>
<td>Malignant melanoma</td>
<td>m</td>
<td>71</td>
<td>2</td>
<td>23</td>
<td>Suspicious for malignancy (follicular or papillary)</td>
<td>Multinodular colloid goitre</td>
</tr>
<tr>
<td></td>
<td>Tumour of the GE junction</td>
<td>f</td>
<td>62</td>
<td>8.7</td>
<td>35</td>
<td>Oncocytic cells</td>
<td>Hürthle adenoma</td>
</tr>
<tr>
<td></td>
<td>Tumour mass in the thigh</td>
<td>m</td>
<td>22</td>
<td>7.8</td>
<td>9</td>
<td>Papillary carcinoma</td>
<td>Follicular carcinoma</td>
</tr>
<tr>
<td></td>
<td>Rectal carcinoma</td>
<td>m</td>
<td>71</td>
<td>2.7</td>
<td>40</td>
<td>Suspicious for follicular malignancy</td>
<td>Follicular carcinoma</td>
</tr>
<tr>
<td></td>
<td>Malignant melanoma</td>
<td>f</td>
<td>55</td>
<td>6</td>
<td>10</td>
<td>Papillary carcinoma</td>
<td>Papillary carcinoma</td>
</tr>
<tr>
<td></td>
<td>Rectal carcinoma</td>
<td>m</td>
<td>59</td>
<td>6.4</td>
<td>10</td>
<td>Papillary carcinoma</td>
<td>Papillary carcinoma</td>
</tr>
<tr>
<td></td>
<td>Rectal carcinoma</td>
<td>m</td>
<td>58</td>
<td>2.8</td>
<td>15</td>
<td>Oncocytic cells</td>
<td>Papillary carcinoma</td>
</tr>
</tbody>
</table>

UMC = University Medical Centre Ljubljana; IO = Institute of Oncology Ljubljana; SUV<sub>max</sub> = maximal standardised uptake value; GE = gastro-oesophageal; GIT = gastro-intestinal tract
Conclusions

Incidental 18F-FDG uptake in the thyroid on PET-CT was found in 3.89%. Only focal thyroid uptake represented a malignant lesion in our study — in 15.2% of all focal thyroid lesions. SUV<sub>max</sub> should only serve as one of several parameters that alert the clinician on the possibility of thyroid malignancy. The correct protocol in this situation is, as recommended by the American Thyroid Association Guidelines, to promptly investigate all focal thyroid PET lesions with additional diagnostics.

References


